Macrolide-Resistant Mycoplasma pneumoniae Infection, Japan, 2008–2015

We evaluated isolates obtained from children with Mycoplasma pneumoniae infection throughout Japan during 2008–2015. The highest prevalence of macrolide-resistant M. pneumoniae was 81.6% in 2012, followed by 59.3% in 2014 and 43.6% in 2015. The prevalence of macrolide-resistant M. pneumoniae among children in Japan has decreased.

[1]  M. Okuda,et al.  Japanese antimicrobial consumption surveillance: First report on oral and parenteral antimicrobial consumption in Japan (2009-2013). , 2016, Journal of global antimicrobial resistance.

[2]  Clementine Fu,et al.  Assessment of Community Event–Based Surveillance for Ebola Virus Disease, Sierra Leone, 2015 , 2016, Emerging infectious diseases.

[3]  Hongjie Yu,et al.  Probable Rabies Virus Transmission through Organ Transplantation, China, 2015 , 2016, Emerging infectious diseases.

[4]  G. Snounou,et al.  Phylogeographic Evidence for 2 Genetically Distinct Zoonotic Plasmodium knowlesi Parasites, Malaysia , 2016, Emerging infectious diseases.

[5]  R. Selvarangan,et al.  Macrolide-Resistant Mycoplasma pneumoniae, United States , 2015, Emerging infectious diseases.

[6]  T. Gebre,et al.  Evidence for clonal expansion after antibiotic selection pressure: pneumococcal multilocus sequence types before and after mass azithromycin treatments. , 2015, The Journal of infectious diseases.

[7]  J. Rupp,et al.  Mycoplasma pneumoniae and Chlamydia spp. Infection in Community-Acquired Pneumonia, Germany, 2011–2012 , 2015, Emerging infectious diseases.

[8]  N. Nomura,et al.  Impact of the pneumococcal conjugate vaccine on serotype distribution and susceptibility trends of pediatric non-invasive Streptococcus pneumoniae isolates in Tokai, Japan over a 5-year period. , 2014, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[9]  Shuyan Qiu,et al.  Epidemiology of Acute Respiratory Infections in Children in Guangzhou: A Three-Year Study , 2014, PloS one.

[10]  Y. Nishizawa,et al.  Nationwide Surveillance of Macrolide-Resistant Mycoplasma pneumoniae Infection in Pediatric Patients , 2013, Antimicrobial Agents and Chemotherapy.

[11]  S. Pereyre,et al.  The increased incidence of Mycoplasma pneumoniae in France in 2011 was polyclonal, mainly involving M. pneumoniae type 1 strains. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  Jiang Wu,et al.  Surveillance of Macrolide-Resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012 , 2012, Antimicrobial Agents and Chemotherapy.

[13]  N. Miyashita,et al.  Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia , 2012, BMC Infectious Diseases.

[14]  M. P. van der Linden,et al.  mef(A) is the predominant macrolide resistance determinant in Streptococcus pneumoniae and Streptococcus pyogenes in Germany. , 2011, International journal of antimicrobial agents.

[15]  N. Miyashita,et al.  Clinical potential of diagnostic methods for the rapid diagnosis of Mycoplasma pneumoniae pneumonia in adults , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[16]  D. Farrell,et al.  Increase in Pneumococcus Macrolide Resistance, United States , 2009, Emerging infectious diseases.

[17]  D. Farrell,et al.  Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004). , 2008, International journal of antimicrobial agents.

[18]  P. Ringwald,et al.  Antimicrobial resistance. , 2001, Emerging infectious diseases.